Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Anteris Technologies Ltd

Company price
None USD 0.00(0%)
Last update at 2025-01-23T19:09:33.313886Z
Market Cap
232.82M

Momentum Score

…

Anteris Technologies Ltd operates as a structural heart company. It manufactures and sells ADAPT, a regenerative tissue product. The company also engages in the developing of DurAVRTM, a 3D single piece aortic valve for the treatment of aortic stenosis. In addition, it researches and develops regenerative medicines. The company was formerly known as Admedus Limited and changed its name to Anteris Technologies Ltd in May 2020. Anteris Technologies Ltd was incorporated in 1999 and is based in Toowong, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
11.82
Low
18.97
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
5.70
Dividend Yield
-
Revenue TTM
4.46M
Revenue Per Share
0.31
Gross Profit TTM
2.61M
Debt / Equity
0.11
ROE
-198.67%
Net Debt
-12.40M
ROCE
-272.46%
Diluted EPS TTM
-2.53

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -44.34M -22.91M -15.27M -6.18M -24.70M
Minority interest - - - 0.36M 0.36M
Net income -44.34M -22.91M -15.27M -5.82M -24.22M
Selling general administrative 22.45M 13.95M 11.76M 20.94M 23.52M
Selling and marketing expenses 1.18M 0.55M 0.59M 1.47M -
Gross profit 2.61M 6.15M 6.51M 8.30M 12.44M
Reconciled depreciation 1.74M 1.35M 1.21M 1.62M 1.41M
Ebit -43.43M -21.57M -14.90M -1.11M -22.06M
Ebitda -41.69M -20.21M -13.69M 0.51M -20.65M
Depreciation and amortization 1.74M 1.35M 1.21M 1.62M 1.41M
Operating income -43.43M -21.57M -14.90M -1.11M -22.06M
Other operating expenses 51.98M 30.80M 25.99M 42.65M 48.09M
Interest expense 0.91M 1.34M 0.37M 0.29M 2.64M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Interest income 0.31M 0.09M 0.19M 0.07M 0.04M
Net interest income -0.77M -1.42M -0.19M -0.22M -2.60M
Income tax expense 4.73M 2.86M 2.25M 24.57M 2.54M
Total revenue 4.59M 7.79M 9.24M 17.08M 25.60M
Total operating expenses 49.99M 29.16M 23.27M 33.88M 34.93M
Cost of revenue 1.98M 1.64M 2.72M 8.77M 13.16M
Total other income expense net 3.81M 1.52M 1.87M 19.86M 0.39M
Net income from continuing ops -44.34M -22.91M -15.27M -6.18M -24.70M
Net income applicable to common shares -44.34M -22.91M -15.27M -5.82M -24.22M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 23.48M 29.48M 12.65M 26.00M 31.86M
Intangible assets 0.90M 1.15M 1.42M 1.70M 3.88M
Other current assets 1.40M 1.20M 1.46M - -
Total liab 10.26M 15.13M 10.24M 10.47M 10.38M
Total stockholder equity 13.22M 14.35M 2.41M 15.54M 21.12M
Other current liab 4.23M 4.56M 4.13M 4.72M 7.13M
Common stock 211.83M 172.64M 138.74M 137.76M 137.74M
Capital stock 211.83M 172.64M 138.74M 137.76M 137.74M
Retained earnings -202.02M -157.68M -134.77M -119.50M -113.68M
Other liab 2.07M 1.77M 1.58M 2.00M 1.61M
Good will - - - - 1.59M
Other assets - - 0.71M 0.73M -
Cash 13.81M 21.30M 4.35M 8.97M 12.04M
Total current liabilities 7.54M 12.94M 7.84M 7.30M 9.60M
Current deferred revenue - - 3.73M 4.32M -
Net debt -12.40M -15.57M -0.57M -6.35M -12.04M
Short term debt 0.76M 5.31M 2.95M 1.45M -
Short long term debt - 4.68M 2.55M 1.11M -
Short long term debt total 1.41M 5.73M 3.78M 2.62M -
Other stockholder equity 3.41M -0.61M -1.56M -2.72M -2.94M
Property plant equipment 4.52M 2.50M 2.43M 2.96M 2.18M
Total current assets 18.07M 25.84M 8.09M 20.58M 22.92M
Net tangible assets 12.32M 13.20M 0.99M 13.81M 14.36M
Short term investments - - - 7.14M -
Net receivables 0.83M 2.59M 1.58M 2.67M 4.19M
Inventory 0.52M 0.76M 0.69M 1.81M 6.69M
Accounts payable 2.55M 3.07M 0.75M 1.13M 2.47M
Accumulated other comprehensive income 3.41M -0.61M -1.56M -2.72M -2.94M
Non currrent assets other - - 0.71M 0.73M 8.94M
Non current assets total 5.41M 3.64M 4.56M 5.42M 8.94M
Capital lease obligations 1.41M 1.05M 1.23M 1.50M -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -1.36M -0.40M 7.11M -7.54M -0.40M
Change to liabilities 0.53M 1.50M -0.91M -2.26M 1.33M
Total cashflows from investing activities -1.36M -1.16M 7.76M 20.57M -1.01M
Net borrowings -2.06M 1.15M 0.82M 0.71M -5.00M
Total cash from financing activities 31.36M 36.91M 1.89M 0.01M 27.15M
Change to operating activities 0.30M -0.07M -0.02M -0.36M 0.16M
Net income -44.34M -22.91M -15.27M -5.82M -24.22M
Change in cash -7.49M 16.95M -4.61M -3.07M 3.78M
Begin period cash flow 21.30M 4.35M 8.97M 12.04M 8.25M
End period cash flow 13.81M 21.30M 4.35M 8.97M 12.04M
Total cash from operating activities -39.00M -18.81M -14.37M -22.87M -22.21M
Issuance of capital stock 34.89M 36.85M 1.07M 0.00M 35.41M
Depreciation 1.72M 1.35M 1.18M 1.23M 1.03M
Dividends paid - -5.00M - - 5.00M
Change to inventory 0.23M -0.06M 1.12M 2.03M -1.14M
Change to account receivables -0.98M -0.05M 5.87M -5.20M 0.53M
Sale purchase of stock -1.47M -1.09M - -0.64M -3.07M
Other cashflows from financing activities -0.71M 3.94M 0.82M 0.65M 4.81M
Change to netincome 2.80M 0.41M -6.47M -12.96M -0.95M
Capital expenditures 2.41M 0.77M 0.29M 0.07M 0.61M
Free cash flow -2.41M -0.77M -0.29M -0.07M -0.61M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ABT
Abbott Laboratories
-0.20
0.19%
103.00 25.97 17.24 3.57 3.20 3.81 16.75
MDT
Medtronic PLC
-0.59
0.59%
100.02 26.60 15.87 3.35 2.08 3.90 14.12
SYK
Stryker Corporation
-
-%
310.00 29.23 16.86 4.18 4.51 4.63 17.16
SEMHF
Siemens Healthineers AG
-
-%
48.34 39.57 21.32 3.01 3.29 2.95 16.92

Profile*

Anteris Technologies Ltd

Anteris Technologies Ltd operates as a structural heart company. It manufactures and sells ADAPT, a regenerative tissue product. The company also engages in the developing of DurAVRTM, a 3D single piece aortic valve for the treatment of aortic stenosis. In addition, it researches and develops regenerative medicines. The company was formerly known as Admedus Limited and changed its name to Anteris Technologies Ltd in May 2020. Anteris Technologies Ltd was incorporated in 1999 and is based in Toowong, Australia.

Toowong Tower, Toowong, QLD, Australia, 4066

61 13 0055 0310

Name Title Year Born
Mr. Wayne G. Paterson CEO, MD & Exec. Director 1967
Mr. Matthew McDonnell Chief Financial Officer NA
Mr. David St. Denis Chief Operating Officer NA
Mr. Stephen Denaro Independent Non-Exec. Director & Company Sec. NA
Mr. Chris Olig Bus. Devel. and Portfolio Planning Director NA
Dr. Chris Meduri M.D., M.P.H. Chief Medical Officer & Member of Medical Advisory Board NA
Mr. Danny Zanardo Commercial Director of International NA
Prof. Ian Hector Frazer AC, FAA, FRS, M.D. Exec. NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…